BioPharma Credit
plc
(the
"Company")
TRANSACTION IN OWN
SHARES
BioPharma Credit PLC announces that
today it has purchased the following number of its ordinary shares
of US$0.01 each through J.P. Morgan Securities plc into
treasury.
Ordinary Shares: BPCR LN
Date of purchase: 25 September
2024
Number of ordinary shares purchased:
550,000
Lowest price per share:
$0.9100
Highest price per share:
$0.9100
Trading venue: JPM SI
Ordinary Shares: BPCR LN
Date of purchase: 25 September
2024
Number of ordinary shares purchased:
320,100
Lowest price per share:
$0.9100
Highest price per share:
$0.9100
Trading venue: LSE
Aggregate volume per date per
trading venue: 870,100
Weighted average price per day per
trading venue: $0.9099
Following the above transaction, the
Company holds 177,626,890 of its ordinary shares in treasury and
has 1,196,305,177 ordinary shares in issue (excluding treasury
shares). Therefore, the total number of voting rights in the
Company is 1,196,305,177. This figure may be used by shareholders
as the denominator for the calculations by which they will
determine if they are required to notify their interest in, or a
change to their interest in, the Company under the FCA's Disclosure
Guidance and Transparency Rules.
Enquiries:
BioPharma Credit plc
via Link Company Matters
Limited
Company Secretary
+44 (0) 333 300 1950
Buchanan
David Rydell / Mark Court
/ Jamie Hooper / Henry Wilson
+44 (0)20 7466 5000
biopharmacredit@buchanan.uk.com
Notes to Editors:
BioPharma Credit
PLC is London's only specialist debt investor to the
life sciences industry and joined the LSE in March
2017. BioPharma Credit PLC seeks to provide long-term
shareholder returns, principally in the form of sustainable income
distributions from exposure to the life sciences
industry. BioPharma Credit PLC seeks to achieve this
objective primarily through investments in debt assets secured by
royalties or other cash flows derived from the sales of approved
life sciences products.
LEI: 213800AV55PYXAS7SY24